Company Overview
GlucoTrack, Inc. operates as a medical device company dedicated to the development of an implantable continuous blood glucose monitor designed for individuals with diabetes within the United States market. The company develops the GlucoTrack, a non-invasive glucose monitoring device intended to assist people with diabetes and pre-diabetes in managing their blood sugar levels effectively. This entity functions within the Healthcare sector, specifically inside the Medical Instruments & Supplies industry, which implies a focus on specialized equipment and diagnostics essential for patient care. The company currently maintains a market capitalization of $1.00M and employs 11 individuals to execute its strategic initiatives. These valuation and staffing figures indicate that GlucoTrack, Inc. operates as a micro-cap entity with a very small operational footprint, suggesting a nascent stage of commercialization where product development likely dominates current expenditures over established sales volumes.
Financial Health
The company reported net income of $-25,854,000 and EBITDA of $-16,384,000 for the trailing twelve months, while revenue data is not available in the current reporting period. The significant gap between the reported revenue figures (which are unavailable) and the substantial net loss reveals a cost structure dominated by high operating expenses, likely driven by research and development efforts required to bring the implantable device to market. Free cash flow stands at $-10,092,875, indicating that the company is currently burning through its liquid assets to fund operations and product development rather than generating surplus cash from its business activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which indicates that the company has not yet achieved profitability on its sales, a common characteristic of pre-revenue or early-stage medical device firms. On the balance sheet, the company holds $7.87M in cash against $3.30M in debt, resulting in a debt-to-equity ratio of 119.88, which suggests a highly leveraged position relative to its equity base despite the cash cushion. The current ratio is 1.53, indicating that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline level of liquidity for day-to-day operations. Return on Equity is listed as N/A due to the lack of profitable earnings, while Return on Assets is -225.7%, revealing that the company's assets are currently generating negative returns and that management effectiveness is constrained by heavy investment costs before commercial success is realized.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that traditional earnings-based valuation multiples cannot be applied until the company generates consistent positive earnings in the future. The price-to-book ratio is 0.32, indicating that the market values the company at significantly less than its book value, often seen in speculative stocks where current assets may not fully reflect the potential value of the underlying technology or pipeline. Since price-to-sales and EV/EBITDA data are unavailable or reported as alternative metrics with EV/EBITDA at 0.22, these figures suggest the market is pricing the stock based on speculative potential rather than current cash flow generation or sales performance. The 52-week high is $17.88 and the 52-week low is $0.96, establishing a trading range that reflects extreme volatility typical of small-cap biotech and medical device companies. The current price sits at a position that fluctuates within this wide range, demonstrating sensitivity to market sentiment regarding the development of the non-invasive glucose monitoring device. The beta value is 0.35, which means the stock's price volatility is significantly lower than the broader market, suggesting that price movements are less correlated with general market indices and more influenced by specific industry developments or company news.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the company's current status where historical growth data is not yet available to measure year-over-year expansion. Without established earnings, the concept of earnings growing faster or slower than revenue is not applicable, as the primary focus remains on product development rather than scaling profitable operations. GlucoTrack, Inc. does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all available cash flow to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is typical for early-stage medical device companies that prioritize long-term technological advancement over immediate income distribution to maintain capital for future growth. The overall growth and income profile is characterized by an absence of current earnings growth and dividend income, with the company's value proposition relying entirely on the future commercial potential of its implantable continuous blood glucose monitor technology.